Clinical Trial

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-19; most recent amendment 2026-02-14.
Status change: Not Yet Recruiting → Recruiting 2026-01-13
Trial Details
NCT Number NCT07251595
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Non-segmental Vitiligo
Enrollment 176 participants
Start Date 2025-12-05
Primary Completion 2027-03 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-18